Nilotinib hydrochloride

Catalog No.S5205 Batch:S520503

Print

Technical Data

Formula

C28H22F3N7O.HCl
Molecular Weight 565.98 CAS No. 923288-95-3
Solubility (25°C)* In vitro DMSO 100 mg/mL (176.68 mM)
Ethanol 2 mg/mL (3.53 mM)
Water Insoluble
In vivo (Add solvents to the product individually and in order)
2% DMSO 40% PEG 300 5%Tween80 53%ddH2O
2.0mg/ml
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Nilotinib hydrochloride (AMN-107) is the hydrochloride salt form of nilotinib, an orally bioavailable Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity.
Targets
Bcr-Abl [1]
(Murine myeloid progenitor cells)
<30 nM

Protocol (from reference)

Selleck's Nilotinib hydrochloride has been cited by 41 publications

Comprehensive multi-omics analysis reveals WEE1 as a synergistic lethal target with hyperthermia through CDK1 super-activation [ Nat Commun, 2024, 15(1):2089] PubMed: 38453961
Preclinical Evaluation of Ixabepilone in Combination with VEGF Receptor and PARP Inhibitors in Taxane-Sensitive and Taxane-Resistant MDA-MB-231 Breast Cancer Cells [ J Pharm Sci, 2022, 111(8):2180-2190] PubMed: 35700798
Targeting Discoidin Domain Receptors DDR1 and DDR2 overcomes matrix-mediated tumor cell adaptation and tolerance to BRAF-targeted therapy in melanoma [ EMBO Mol Med, 2021, e11814] PubMed: 34957688
Antimetabolic cooperativity with the clinically approved l-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells [ Mol Metab, 2021, 55:101410] PubMed: 34863941
CXCR2, a novel target to overcome tyrosine kinase inhibitor resistance in chronic myelogenous leukemia cells [ Biochem Pharmacol, 2021, 190:114658] PubMed: 34146540
Imatinib can act as an Allosteric Activator of Abl Kinase [ J Mol Biol, 2021, 434(2):167349] PubMed: 34774565
Statins Enhance the Molecular Response in Chronic Myeloid Leukemia when Combined with Tyrosine Kinase Inhibitors [ Cancers (Basel), 2021, 13(21)5543] PubMed: 34771705
Extension of the Mechanistic Tissue Distribution Model of Rodgers and Rowland by Systematic Incorporation of Lysosomal Trapping: Impact on Unbound Partition Coefficient and Volume of Distribution Predictions in the Rat [ Drug Metab Dispos, 2021, 49(1):53-61] PubMed: 33148688
ABL1 and Cofilin1 promote T-cell acute lymphoblastic leukemia cell migration [ Acta Biochim Biophys Sin (Shanghai), 2021, gmab117] PubMed: 34508625
Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1T315I and BCR-ABL1T315I-E255K [ Ann Hematol, 2021, 10.1007/s00277-020-04357-z] PubMed: 34110462

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.